PARP Inhibitor Active in BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer
The search for biomarkers in prostate cancer has proved frustrating, partly due to the complexity of the disease and its heterogeneity. A preliminary analysis of a phase II (TRITON2) study suggests that rucaparib
Pembrolizumab Triplet Shows Activity in BRAF-Mutant Melanoma
As first-line treatment of advanced BRAF-mutant melanoma, pembrolizumab (Keytruda) added to dabrafenib (Tafinlar) and trametinib (Mekinist) produced a nonsignificant improvement in...
No Benefit for Atezolizumab Plus Standard of Care for Maintenance in Colorectal Cancer Subset
Adding atezolizumab (Tecentriq) to a fluoropyrimidine plus bevacizumab (Avastin) did not improve outcomes for patients with BRAF wild-type metastatic colorectal cancer enrolled in the umbrella
HDAC Inhibitor May Overcome Endocrine Resistance in Advanced Breast Cancer
Epigenetic changes are associated with the development of cancer, and epigenetic therapy is an attractive strategy for targeting the tumor microenvironment. One approach targeted to epigenetic changes...
Bladder Cancer: Strategies to Address Checkpoint Inhibitor Failure
Checkpoint inhibitors have rapidly become the standard of care as second-line treatment, and in some patients first-line treatment, of advanced bladder cancer. However, the majority of patients do not respond...
Donald Abrams: Should Oncologists Recommend Cannabis?
William Sharfman: Encorafenib and Binimetinib in Metastatic Melanoma
Amitabh Gulati: Challenges Presented by the Parenteral Opioid Shortage
Timothy Triche: Genomic Profiling in Younger Patients With Cancer
Christopher Wild: Global Burden of Cancer on the Rise
More Top Stories
University Collaboration Aims to Tackle Cancer Health Disparities
The National Cancer Institute has provided a grant to develop a joint cancer drug discovery/development and research education program to focus on cancers that have an increased risk of incidence and/or mortality among underserved communities, namely African Americans, Hispanics, and Native...
Aggressive Squamous Cell Carcinoma in Recipients of Solid Organ Transplant Recipients
Squamous cell carcinoma (SCC) is the most frequently diagnosed cancer in recipients of a solid organ transplant. When organ transplant recipients are diagnosed with SCC, they are also at higher risk for a more aggressive disease course, metastasis, and death than the general population. Researchers ...
Unequal Burden of Cancer-Related Suffering and Need for Palliative Care
The global burden of cancer-related suffering is tremendously unbalanced, according to Eric L. Krakauer, MD, PhD, Director of the Global Palliative Care Program at Massachusetts General Hospital and Harvard Medical School, Boston and a lead coauthor of the Report of the Lancet Commission on Global...
Shedding Light on Mechanisms of Resistance to Treatment of Metastatic Castration-Resistant Prostate Cancer
ONE OF the pressing issues in metastatic castration-resistant prostate cancer is the development of resistance to therapies directed at the androgen receptor (AR), such as enzalutamide (Xtandi) and abiraterone acetate (Zytiga). Research is ongoing to identify mechanisms of resistance in the hope of ...
CIMRA Assay for Detection of Gene Variants in Lynch Syndrome
An international team of researchers has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease. The results were published by Drost et al in Genetics in Medicine. ...
The Politics and Economics of Cancer Prevention
Finance is a key driver in cancer prevention, as has been evidenced by the influence of tax on the consumption of products such as cigarettes and alcohol. Going up against a huge industry like Big Tobacco will almost certainly be met with tremendous opposition, but understanding the industrial...
Addition of Veliparib to Cisplatin/Etoposide in Extensive-Stage SCLC
In the phase II ECOG-ACRIN 2511 trial reported in the Journal of Clinical Oncology, Owonikoko et al found that the addition of the poly (ADP ribose) polymerase (PARP) inhibitor veliparib to cisplatin/etoposide was associated with a modest but statistically significant improvement in...
Eva M. Ciruelos, MD, PhD, on HER2-Positive Breast Cancer: Results From the PATRICIA Trial
Xavier Pivot, MD, PhD, on Early Breast Cancer: Results From the PHARE Trial
Harold J. Burstein, MD, PhD, and Daniel F. Hayes, MD, on Breast Cancer With Positive Lymph Nodes: Treatment Controversy
Judy E. Garber, MD, on Cancer Genetics: Updates for Breast Cancer Care
